Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

Blood–brain barrier dysfunction in parkinsonian midbrain in vivo

Rudie KortekaasDepartment of Neurology, Groningen University Hospital, Groningen, The NetherlandsKlaus L. LeendersDepartment of Neurology, Groningen University Hospital, Groningen, The NetherlandsJoost C.H. van OostromDepartment of Neurology, Groningen University Hospital, Groningen, The NetherlandsWillem VaalburgPET-centre, Groningen University Hospital, Groningen, The NetherlandsJoost BartDepartment of Pathology, Groningen University Hospital, Groningen, The NetherlandsAntoon T. M. WillemsenPET-centre, Groningen University Hospital, Groningen, The NetherlandsN. Harry HendriksePET-centre, Groningen University Hospital, Groningen, The Netherlands
2005en
ABI

Аннотация

Parkinson's disease (PD) is associated with a loss of neurons from the midbrain. The cause of PD is unknown, but it is established that certain neurotoxins can cause similar syndromes. The brain is normally protected from these noxious blood-borne chemicals by the blood-brain barrier which includes specialized proteins on the inside of blood vessels in the brain. These act as molecular efflux pumps and P-glycoprotein (P-gp) is an abundant representative. Vulnerability to PD appears codetermined by the genotype for the P-gp gene. We hypothesized that PD patients have reduced P-gp function in the blood-brain barrier. We used positron emission tomography to measure brain uptake of [(11)C]-verapamil, which is normally extruded from the brain by P-gp. Here, we show significantly elevated uptake of [(11)C]-verapamil (18%) in the midbrain of PD patients relative to controls. This is the first evidence supporting a dysfunctional blood-brain barrier as a causative mechanism in PD.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0